Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

NESS-0327NESS 0327

Tricyclic pyrazole CB1 antagonist, presented as neutral; femtomolar Ki of 2003 revised to nanomolar in 2016 (4.2 to 126 nM depending on the assay).

Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₂₄H₂₃Cl₃N₄O

CAS 494844-07-4

Family
ECS pharmacological toolAntagonist or inverse agonist
Molar mass
489.80 g/mol

Updated on

In plain terms

NESS 0327 is a laboratory molecule that blocks the CB1 receptor, like rimonabant. In 2003 its authors credited it with extraordinary affinity; in 2016 part of the same group corrected these measurements to values in the nanomolar range. In animals it has been described as a "neutral" blocker. No study in humans was found.

Receptors and activity

Target network

CB1AntagonistKi = 4.2 nM · mouse[3H]CP-55940 displacement, whole mouse brain membranes (4.2 nM; a second determination at 8.18 nM); 126 nM at human CB1 (CHO cells); re-evaluation of 2016 which replaces the 350 fM value of 2003; read in ChEMBL (document CHEMBL3856211)
  • Blocks or inhibits
  • Binds or modulates

The lower the cited value, the closer the target sits to NESS-0327: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of NESS-0327.

Brain, side view
Body, front view
Blood

CB1CB1 found in 7 regions of the body

  1. Basal gangliadenseMost dense in basal ganglia outflow nuclei1
  2. CerebellumdenseVery dense in the cerebellum1
  3. HippocampusdenseVery high concentrations in the hippocampus2
  4. AmygdaladenseHigh concentrations in the amygdala2
  5. CortexpresentPresent throughout the neocortex2
  6. Adipose tissuepresentExpressed in adipose tissue3
  7. GutpresentColonic epithelium, smooth muscle and plexus4

Cited values

  1. CB1AntagonistKi = 4.2 nM · mouse73 out of 100

    Lazzari et al., Eur J Med Chem 2016 (values read in ChEMBL, document CHEMBL3856211) (new tab) · [3H]CP-55940 displacement, whole mouse brain membranes (4.2 nM; a second determination at 8.18 nM); 126 nM at human CB1 (CHO cells); re-evaluation of 2016 which replaces the 350 fM value of 2003; read in ChEMBL (document CHEMBL3856211)

  2. CB2Binding (function not established)Ki = 55.7 nM · human54 out of 100

    Lazzari et al., Eur J Med Chem 2016 (values read in ChEMBL, document CHEMBL3856211) (new tab) · [3H]-CP55,940 displacement, human CB2 transfected into CHO cells (55.7 nM; a second determination at 85.2 nM); 2016 re-evaluation; read in ChEMBL (document CHEMBL3856211)

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

NESS 0327 is a tricyclic pyrazole CB1 receptor antagonist, a derivative of rimonabant whose skeleton is closed into a constrained system. In 2003, Ruiu and colleagues described it with an affinity of 350 fM for CB1 and a selectivity of more than 60,000-fold over CB2, values that for a time made it the highest-affinity CB1 antagonist published (Ruiu et al. 2003). These values did not survive reproduction: other laboratories measured nanomolar affinities, and in 2016 part of the original group itself reported a nanomolar rather than femtomolar Ki (Lazzari et al. 2016), with, according to ChEMBL, values of 4.2 to 8.18 nM at mouse CB1 and 126 nM at human CB1. It is still described as a CB1 antagonist: it did not stimulate [35S]GTPγS by itself, antagonised the effects of WIN 55,212-2 in vitro and in vivo (Ruiu et al. 2003) and, unlike rimonabant, does not suppress the constitutive activity of CB1; in the work of Meye and colleagues it reduced weight gain and food intake in laboratory animals like rimonabant, without the anxiety and reduced motivation for reward seen with that drug (Meye et al. 2013). These results are preclinical; no study in humans was found.

History

Source
An entirely synthetic compound with no natural occurrence. It is known as an experimental pharmacology reagent; no clinical development was found in the sources consulted.

Origin

Research tool

No biological pathway: NESS 0327 is a synthetic compound of the tricyclic pyrazole class, unrelated to the plant cannabinoid pathway.

Classification

Family, origin and source verification

Family

ECS pharmacological tool › Antagonist or inverse agonist

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

NESS-0327 (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

References

Identifiers

Names

Common name
NESS 0327
IUPAC name
12-chloro-3-(2,4-dichlorophenyl)-N-piperidin-1-yl-3,4-diazatricyclo[8.4.0.02,6]tetradeca-1(10),2(6),4,11,13-pentaene-5-carboxamide
Other names
NESS0327

Identifiers

Formula
C₂₄H₂₃Cl₃N₄O
CAS
494844-07-4
InChIKey
NCXBPZJQQSNIRA-UHFFFAOYSA-N
SMILES
C1CCN(CC1)NC(=O)C2=NN(C3=C2CCCC4=C3C=CC(=C4)Cl)C5=C(C=C(C=C5)Cl)Cl

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.